Preoperative concentrations, expressed as percentages of the upper reference limit (dashed line), for plasma metanephrines, plasma catecholamines, and urinary excretion of catecholamines. Data are presented for individual patients with pheochromocytoma (PHEO) and histologically verified other adrenal tumors (OAT).
Plasma metanephrines and catecholamines in the recumbent and upright positions in patients with pheochromocytoma (PHEO) and those with other adrenal tumors (OAT). Individual absolute concentrations are given. Median values are represented by full horizontal lines. Blood samples were drawn after 20 minutes in the recumbent position and subsequently after 10 minutes in the upright position from an indwelling forearm catheter. To convert values for plasma measurements to picomoles per liter, multiply by 5.46 for normetanephrine, 5.91 for norepinephrine, 5.08 for metanephrine, and 5.46 for epinephrine.
Intraoperative plasma concentrations of metanephrines and catecholamines at the beginning of surgery and during maximal mechanical tumor manipulation in patients with pheochromocytoma (PHEO) and those with other adrenal tumors (OAT). Individual absolute concentrations are given. Median values are represented by full horizontal lines. Blood samples were drawn from an indwelling central venous catheter. To convert values for plasma measurements to picomoles per liter, multiply by 5.46 for normetanephrine, 5.91 for norepinephrine, 5.08 for metanephrine, and 5.46 for epinephrine.
Intraoperative time course of plasma concentrations of metanephrines and catecholamines after clipping of the adrenal vein (zero time). Absolute plasma concentrations are given from 20 minutes before until 175 minutes after separation of the tumor from blood circulation in patients with sporadic (n = 5) and familial (n = 1) pheochromocytoma who underwent endoscopic adrenal surgery. To convert values for plasma measurements to picomoles per liter, multiply by 5.46 for normetanephrine, 5.08 for metanephrine, 5.91 for norepinephrine, and 5.46 for epinephrine.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Raber W, Raffesberg W, Bischof M, et al. Diagnostic Efficacy of Unconjugated Plasma Metanephrines for the Detection of Pheochromocytoma. Arch Intern Med. 2000;160(19):2957–2963. doi:10.1001/archinte.160.19.2957
Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000
Recently, measurement of plasma metanephrines was suggested to improve the detection of pheochromocytoma compared with the other common biochemical tests.
To examine the diagnostic precision of measurements of plasma metanephrines, plasma catecholamines, and urinary catecholamines and to assess their variability.
Plasma metanephrine as well as plasma and urinary catecholamine concentrations were measured by high-performance liquid chromatography with electrochemical detection. Before surgery, responses of plasma metanephrines and catecholamines to change of posture were determined. Intraoperatively, metanephrines and catecholamines were measured before skin incision, during maximal mechanical tumor manipulation, and repetitively after the tumor was separated from the circulation. Patients were reexamined 1 and 3 months after surgery. Patients with pheochromocytoma (n = 17) and with histologically proved other adrenal tumors (n = 14) were studied before, during, and after surgery.
Measurement of plasma metanephrines and plasma and urinary catecholamines provided 100% and 82% sensitivity, respectively, for the detection of pheochromocytoma (P<.001). Levels of plasma catecholamines but not metanephrines increased in response to change of posture (norepinephrine, P = .03; epinephrine, P = .07) and intraoperative stress (norepinephrine, P = .002; epinephrine, P = .009).
Plasma metanephrines offer improved efficacy for the diagnosis of pheochromocytoma. Less variability in response to external factors may favor plasma metanephrines in the screening for this disease.
DIAGNOSIS OF pheochromocytoma still poses considerable problems, as almost half of patients initially have no or only paroxysmal hypertension or may even be asymptomatic.1 Even the classic symptom triad of bilateral diffuse headache, sweating, and palpitations provides diagnostic accuracy of only 6%.2 Autopsy studies show that the disease is not recognized in 20% to 75% of patients during life but represents the cause of death in half of them.3,4 Proper diagnosis of pheochromocytoma by highly sensitive biochemical tests therefore remains of paramount importance.
Simple biochemical screening, largely independent of external influences such as posture or stress, in general should improve the diagnostic sensitivity. Improved accuracy in the diagnosis of pheochromocytoma has been suggested5 with the use of determination of plasma metanephrines (metanephrine and normetanephrine), the O-methylated extraneuronal metabolites of catecholamines, by high-performance liquid chromatography with electrochemical detection.6 Recently, an extended report by Eisenhofer et al7 favored plasma metanephrines in particular for oligosymptomatic, and even asymptomatic subjects at high risk for pheochromocytoma, such as patients with von Hippel–Lindau disease or family members of patients with multiple endocrine neoplasia type 2 (MEN 2).7 However, the superiority of plasma metanephrines has not yet been supported by others.
The aims of this study were (1) to compare the diagnostic efficacy of plasma catecholamines and metanephrines, (2) to investigate the suggested independence8 of plasma metanephrines of large increases in plasma catecholamine concentrations in patients with pheochromocytoma compared with those with histologically proved other adrenal tumors, and (3) to observe the intraoperative time course of metanephrine and catecholamine levels in patients with pheochromocytoma.
We studied 17 patients with pheochromocytoma and 14 patients with histologically verified other adrenal tumors (Table 1). In 3 patients the diagnosis of MEN 2A was proved by identification of germline mutations of the RET proto-oncogene. Fourteen patients with pheochromocytoma (all but 1 with sporadic disease) had sustained hypertension (systolic blood pressure of >140 mm Hg or diastolic blood pressure of >90 mm Hg). Two other patients (1 with sporadic pheochromocytoma and 1 with MEN 2A) had documented periods of intermittent hypertension. All patients with hypertension and an additional patient with normal blood pressure (with the familial disease) also reported symptoms of pheochromocytoma (eg, headache, palpitations, or excessive sweating). Patients with histologically confirmed other adrenal diseases served as a reference group (Table 1).
Three 24-hour urine samples (of which the highest concentrations are given) for the determination of norepinephrine and epinephrine were obtained before surgery, and one 24-hour urine collection was obtained at 1 and at 3 months after surgery. Blood samples for the determination of normetanephrine, metanephrine, norepinephrine, and epinephrine in plasma were drawn into 10-mL heparinized tubes through an intravenous cannula in the forearm. Patients rested in the supine position for 20 minutes before blood sampling. Additional blood samples were subsequently collected after 10 minutes in the upright position in all patients. Blood pressure and heart rate were measured repeatedly. None of the patients was taking acetaminophen, which can interfere with the plasma normetanephrine assay.6 Intraoperatively, blood was obtained at baseline (after intubation, before skin incision) and during maximal mechanical tumor manipulation in 15 patients. Blood samples were also drawn from a central venous cannula immediately before and repeatedly after clipping of the adrenal vein to follow the time course of plasma metanephrine and catecholamine levels in 6 patients. All blood samples were transferred into prechilled heparinized tubes, immediately placed on ice, and centrifuged (4°C, 2000 rpm) within 15 minutes to separate the plasma. Plasma was stored at −80°C before assay. The study was approved by the appropriate institutional review boards, and all patients gave their informed consent to participate.
The high-performance liquid chromatography method for the determination of plasma metanephrines6 was optimized by modifications in the extraction and chromatographic procedures. Briefly, extraction was performed on solid-phase extraction columns (Isolute SCX; International Sorbent Technology, Hengoed, South Wales), and an electrochemical detector with microdialysis cells (Colouchem II; ESA, Chelmsford, Mass) was used for chromatography. This allowed detection of plasma concentrations of normetanephrine as low as 55 pmol/L and of metanephrine as low as 82 pmol/L. Recovery was estimated to range from 90% to 105% of the internal standard. The interassay coefficients of variation were 5% (normetanephrine) and 8% (metanephrine) at physiologic plasma hormone concentrations ±1 SD (normetanephrine, 430 ± 30 pmol/L; metanephrine, 150 ± 10 pmol/L). Upper limits of the normal range were adapted from Lenders et al5 to allow comparison of results (normetanephrine, 660 pmol/L; metanephrine, 300 pmol/L; norepinephrine, 3000 pmol/L; and epinephrine, 540 pmol/L).
Plasma catecholamines were analyzed by reverse-phase high-performance liquid chromatography9 with the use of plasma catecholamine extraction tubes (ESA) for the isolation procedure. Interassay and intra-assay coefficients of variance were less than 5% for both compounds.
Urine samples were collected in plastic flasks containing 10 mL of 25% hydrochloric acid. After extraction by ion-exchange columns and separation by high-performance liquid chromatography, catecholamines were measured by electrochemical detection (Pharmacia KB, Uppsala, Sweden) by means of kits (Chromsystem, Munich, Germany).
The 3 tests involved the determination of 2 compounds (plasma normetanephrine and metanephrine, plasma norepinephrine and epinephrine, and urinary norepinephrine and epinephrine). A positive or negative result was defined as normal or elevated values, respectively, for both substances in the pair. Preoperative values were obtained before the institution of α-blockade in 16 patients. Two patients (1 with life-threatening paroxysms of hypertension and 1 with sustained hypertension >250/140 mm Hg) had been taking this medication for 3 and 10 days before the first blood sample was drawn. Diagnostic procedures were evaluated by sensitivity, specificity, and positive and negative predictive values.10
Comparisons of sensitivity or specificity between plasma metanephrines and other biochemical tests were performed with the use of the McNemar test.11 Median increases of plasma metanephrine and catecholamine concentrations during the upright position test and the maximum intraoperative stress, respectively, were analyzed by the Wilcoxon rank sum test. The differences in the extent of increase above the upper reference limit of normal among the biochemical tests (both preoperatively and during surgery) were compared by analysis of variance with Scheffé post hoc test. The correlation between tumor mass and biochemical test results was described by the Spearman rank correlation.
All patients with pheochromcytoma were separated from all patients with other adrenal tumors by determination of plasma normetanephrine level (Figure 1). Plasma metanephrine testing was falsely negative in 5 of the 17 patients with pheochromocytoma. However, these 5 patients (4 with adrenal tumors and 1 with an extra-adrenal sporadic tumor) had elevated normetanephrine concentrations. Thus, measurement of plasma normetanephrine with or without metanephrine was positive in all patients with pheochromocytoma.
In contrast, plasma norepinephrine level was normal in 4 patients with pheochromocytoma (2 with sporadic and 2 with familial adrenal tumors). Plasma epinephrine level was normal in 9 of 17 patients with pheochromocytoma (2 with familial adrenal tumors, 6 with sporadic adrenal tumors, and 1 with a sporadic extra-adrenal tumor). Three of these patients had elevated plasma norepinephrine concentrations. Both plasma norepinephrine and epinephrine levels were therefore normal in 3 of 17 patients with pheochromocytoma (Figure 1).
Similarly, urinary norepinephrine concentration was normal in 5 patients with pheochromocytoma (3 with sporadic and 2 with familial adrenal tumors). One of these patients (with sporadic adrenal disease) had elevated urinary epinephrine concentration. Seven patients with pheochromocytoma (1 with a familial tumor, 5 with sporadic adrenal tumors, and 1 with a sporadic extra-adrenal tumor) had urinary epinephrine concentrations within the normal range. Four of them, however, had elevated urinary norepinephrine excretion. Overall, urinary norepinephrine and epinephrine levels were within the normal range in 3 of 17 patients with pheochromocytoma (Figure 1).
The sensitivity of plasma metanephrines (normetanephrine and metanephrine) for the diagnosis of pheochromocytoma was 100% and thus 17% higher than that of plasma (82%; P<.001) and urinary (82%; P<.001) norepinephrine and epinephrine concentrations (Table 2).
In patients with pheochromocytoma, plasma normetanephrine concentrations were increased up to approximately 1000% above the upper reference limit (Figure 1), which was not larger (P = .77) than the increase in plasma norepinephrine level but considerably higher (P<.001) than that in plasma metanephrine (600%) and epinephrine (400%) concentrations, and in the urinary excretion of norepinephrine (600%) and epinephrine (550%).
Mean plasma norepinephrine concentration increased (P = .03) in all patients with pheochromocytoma by 300% in response to change to the upright position (Figure 2). The median increase was 19,858 pmol/L (range, 1478-35,460 pmol/L), whereas plasma normetanephrine concentrations did not change significantly. Plasma epinephrine displayed a trend (P = .07) to rise (median increase, 546 pmol/L; range, 27-8190 pmol/L) in 14 patients. Four patients (who had adrenal pheochromocytoma with normal plasma epinephrine levels) had identical or lower plasma epinephrine concentrations in the upright compared with the supine position. Plasma metanephrine concentrations were not significantly different.
Similarly, plasma norepinephrine level was increased (P = .02) in the upright posture, while plasma concentrations of epinephrine (P = .09), normetanephrine, and metanephrine were not significantly higher in patients with other adrenal tumors (Figure 2).
Plasma norepinephrine concentrations rose (P = .002) markedly during surgery (Figure 3) in all patients with pheochromocytoma (median increase, 164,000 pmol/L; range, 6800-2,240,000 pmol/L) when measured during maximal mechanical tumor manipulation and compared with that before skin incision. Plasma normetanephrine level did not change significantly (median increase, 7370 pmol/L; range, 300-22,600 pmol/L). Plasma epinephrine level increased (P = .009) markedly in all patients (median increase, 24,730 pmol/L; range, 440-371,280 pmol/L), while plasma metanephrine level did not. Again, the extent of increase above the upper reference limit of normal in response to intraoperative mechanical stress was higher (P<.001) for plasma catecholamines than for plasma metanephrines. Similar results were obtained in patients with other adrenal tumors (Figure 3).
The size of the tumor in patients with pheochromocytoma but not in those with other adrenal tumors correlated positively with the preoperative plasma concentrations of normetanephrine (r = 0.70; P<.001) and metanephrine (r = 0.62; P<.001) but not with plasma norepinephrine (r = 0.18; P = .86) or epinephrine (r = 0.28; P = .68).
Plasma concentrations of catecholamines and metanephrines were studied in 6 patients during unilateral laparoscopic adrenal surgery for sporadic (n = 5) and familial (n = 1) pheochromocytoma (Figure 4). A transient increase in catecholamine level and, to a lesser extent, in metanephrine level was seen after clipping of the adrenal vein and before a fall in the respective plasma concentrations.
Fourteen (88%) of 16 patients displayed normal biochemical results in all tests at 3 months after surgery (median values, 290 pmol/L for normetanephrine, 76 pmol/L for metanephrine, 1890 pmol/L for norepinephrine, and 87 pmol/L for epinephrine). One patient with MEN 2A displayed continuously increasing plasma metanephrine concentrations at 1 month (290 pmol/L), 3 months (533 pmol/L), and 6 months (645 pmol/L) after unilateral adrenal surgery despite a negative postoperative iodine 131 [131I] meta-iodobenzyl guanidine (MIBG) scan. Another patient with the familial disease had increased plasma metanephrine level (498 pmol/L), borderline plasma normetanephrine level (628 pmol/L), and elevated urinary epinephrine excretion (41 µg/24 h). This patient remained asymptomatic and refused further diagnostic and therapeutic procedures.
Plasma concentrations of unconjugated normetanephrine and metanephrine showed superior sensitivity (P<.01) for the diagnosis of pheochromocytoma compared with plasma and urinary catecholamines. While plasma and urinary catecholamines were increased in only 83% of patients, plasma metanephrines were elevated in all patients. This is in keeping with previous findings in sporadic pheochromocytoma6 and, more recently, MEN 2 and von Hippel–Lindau disease.5 In particular, all patients with pheochromocytoma in our study could be identified by determination of plasma normetanephrine alone. Thus, one patient with a small pheochromocytoma and normal plasma normetanephrine concentrations described by Eisenhofer et al7 continues to represent the only false-negative normetanephrine result reported so far in histologically confirmed pheochromocytoma.
The present study also found that plasma metanephrine concentrations are largely unsusceptible to external influences such as change of posture (Figure 2) or the mechanical stress imposed by either endoscopic or open surgery (Figure 3). In contrast, large increases in plasma catecholamine levels were observed in response to these procedures, findings that were observed equally in patients with pheochromocytoma and those with histologically documented other adrenal tumors. This is in keeping with results obtained by others in humans (by means of glucagon stimulation or insulin hypoglycemia tests) that show plasma metanephrine levels to be insensitive to short-term increase of plasma catecholamine levels.8 This independence of external influences indicates that determination of plasma metanephrine levels will not require time-consuming standardization of blood sampling necessary for correct determination of plasma catecholamine levels and will be therefore more suitable as a screening test.
Tumor volume was highly correlated with plasma metanephrine concentrations but not with plasma catecholamine levels, supporting evidence that metanephrines are produced by catechol-O-methyltransferase within tumors.8 This is in keeping with previous findings in sporadic pheochromocytoma.5
While the adrenal gland constitutes the single largest source of metanephrine and normetanephrine, contributing more than 90% of metanephrine and up to 40% of normetanephrine in plasma, only approximately 7% of plasma norepinephrine is derived from the adrenal glands, with the remainder being derived from sympathetic nerves.12 About 3.5 times more norepinephrine than normetanephrine that is normally secreted by the adrenal glands would therefore have to be produced by an adrenal pheochromocytoma to increase the respective plasma concentrations to above the upper limit of normal, which has been suggested to explain the higher sensitivity of plasma normetanephrine for detection of pheochromocytoma.7
Plasma norepinephrine concentrations, on the other hand, do not directly reflect sympathetic neural activity13 despite the fact that sympathetic nerves contribute by approximately 93% to plasma norepinephrine.12 Sympathetic neural activity, ie, the body's adaptation to "flight-or-fight" situations (including increased heart rate, blood pressure, or sweating), is accomplished by only a small portion of the neuronally produced transmitter. Most secreted norepinephrine undergoes neuronal reuptake, either into the axon itself or into dendrites of nearby cells in an autocrine and paracrine fashion to modify overall sympathetic acitivity.14 Alternatively, norepinephrine can escape from nerve cells into plasma. The spillover of norepinephrine from the neural cleft, the reuptake into the nerve terminal, and the local metabolism of norepinephrine may differ considerably from one stress situation to another, explaining the lack of correlation between plasma norepinephrine concentrations and clinical features such as blood pressure.15,16 Plasma catecholamine levels are therefore, by nature, imprecise markers of a disease such as pheochromocytoma.
Intraoperatively, plasma catecholamines and metanephrines would be expected to rapidly decline after maximal mechanical tumor manipulation. Repetitive blood sampling, however, showed a transient increase of both metanephrine and catecholamine concentrations, even after clipping of the adrenal vein, and a slow decline thereafter (Figure 3). Release of catecholamines and metanephrines from as yet undefined compartments17 could explain this phenomenon after the tumor is separated from blood circulation. In addition, the slow decline in the subsequent period suggests continuous production and/or release from storage sites (eg, platelets, endothelium) of plasma catecholamines and metanephrines after clipping of the adrenal vein, not compatible with half-lives of 1 to 2 minutes (catecholamines) and 3 to 5 minutes (metanephrines) reported in clearance studies of these compounds.13,18
In conclusion, determination of plasma metanephrine and, in particular, normetanephrine levels offers improved efficacy for the detection of pheochromocytoma. Less variability in response to external factors may favor determination of metanephrine levels in screening for and postoperative control of the disease.
Accepted for publication April 28, 2000.
Reprints: Michael Roden, MD, Division of Endocrinology and Metabolism, Department of Medicine III, University of Vienna, Währinger Gürtel 18-20, A-1090 Wien, Austria (e-mail: Michael.Roden@AKH-Wien.ac.at).